Eli Lilly and Company (LLY) is listed on NYSE in the Healthcare sector Β· Drug Manufacturers - General industry. The current price is 1154.22, down -0.50% from the previous close. Market cap is approximately $1.03T.
The commentary below is auto-generated by comparing market data (P/E, ROE, D/E, etc.) against predefined thresholds. No LLM is used. This is not a buy/sell recommendation from us or any analyst. For reference only.
Eli Lilly and Company trades at a premium P/E of 38.92x, with a lot of growth priced in. A single quarter that misses consensus can compress the multiple sharply.
Eli Lilly and Company's 102.29% ROE places it in the elite band. Companies that sustain ROE above 15% for years usually have a structural moat (brand, network effects, cost advantage).
LLY's D/E at 162.07 is on the high side. Credit rating, debt maturity ladder, and refinancing risk all become first-order considerations.
Revenue is growing 47.70% year-over-year. Double-digit growth often reflects share gains or new-market entry.
Eli Lilly and Company's 0.60% yield falls short of typical income-investor thresholds. A consistent double-digit dividend growth rate can still compound meaningfully over time.
Clinical trial outcomes, FDA decisions, and drug-pricing policy drive most of the short-term volatility.
Eli Lilly and Company trades in the upper 24% of its 52-week range (712.05β1293). The uptrend is intact, though how much optimism is already reflected in the price is a separate question worth checking.
Your watchlist and portfolio, one tap from your home screen β the Margin Call app
The day's high-to-low spread reached 3.00%, with a -0.50% move. Wide sessions frequently follow earnings, filings, or sector news, so identifying the catalyst matters.
Eli Lilly and Company (LLY) is listed on NYSE, with recent volume of 722,103 shares. Volume is a supporting gauge of how much conviction sits behind a price move β the same gain reads differently on heavy versus light turnover.